Lite Strategy, Inc. (LITS) company profile
Close on Nov 17, 2026Market cap $24.17MP/E –Yield –
About Lite Strategy
Finance Services, SIC 6199
Lite Strategy, Inc. is a biopharmaceutical company engaged in pre-clinical development programs for non-oncologic disease indications, after historically developing cancer therapies. The company's drug candidate pipeline features voruciclib, an orally administered cyclin-dependent kinase 9 inhibitor, and zandelisib, an oral selective PI3Kδ inhibitor. In addition to pharmaceutical research, the company maintains Litecoin as a primary treasury reserve asset and manages covered call option strategies on its digital asset holdings. Potential customers and commercial partners include biotechnology and pharmaceutical companies, research institutions, and healthcare collaborators targeted for out-licensing, program sales, or clinical development partnerships.
Because the company is focused on early-stage drug candidate research and treasury management, it does not operate commercial retail stores, manufacturing facilities, or consumer service locations. Operational, regulatory, and patent activities are carried out primarily in the United States, alongside patent holdings across international jurisdictions. The provided text does not disclose the location of the company's corporate headquarters.
Summary of the business section of Lite Strategy's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lite Strategy, Inc.
- Headquarters
- San Diego, CA
- Address
- 9920 Pacific Heights Blvd, Suite 150 92121
- Phone
- (858) 369-7100
- Website
- litestrategy.com
- Employees
- 5, Jun 30, 2026
- Industry
- Finance Services
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- Deloitte and Touche LLP, San Diego, California
Stock & identifiers
- Ticker
- LITS
- Former tickers
- MEIP until Sep 15, 2025
- Exchange
- Nasdaq
- IPO date
- Dec 18, 2003
- Shares outstanding
- 30M, Sep 22, 2026
- Public float
- $43.00M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Apr 17, 2023; 1-for-6 reverse, Dec 19, 2012; 1-for-10 reverse, Mar 31, 2010
- SEC CIK
- 1262104
- CUSIP
- 55279B202
- ISIN
- US55279B2025
- FIGI
- BBG000BSGT68
- Share class FIGI
- BBG001SBWG10
- LEI
- 529900A43X33ON524197
- EIN
- 51-0407811
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Justin J. File | CEO, CFO and Secretary, Director | – |
| Nicholas Glover | Director | 2,000 |
| Frederick W. Driscoll | Director | 1,875 |
| James P. Flynn | Director | 125,000 |
| Joshua Riezman | Director | – |
| Charles Benjamin Lee | Director | 292,397 |
| Steven D. Wood | Director | 72,092 |
| Thomas C. Reynolds | Director | 500 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 | $1.58M | $1.43M | – | $18 | – |
| FY2025 | $912.67K | $893.20K | – | $48 | – |
| FY2024 David MUrso | $894.91K | $220.79K | $730.91K | $57 | – |
| FY2024 David Urso | $894.91K | $233.57K | $730.91K | $57 | – |
| FY2023 Daniel Gold | $2.45M | $1.85M | $772.49K | $54 | $109 |
| FY2023 Daniel PGold | $2.45M | $1.86M | $772.49K | $54 | $109 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Justin J. File Acting Chief Executive Officer, Chief Financial Officer | $541.67K | $371.00K | – | $912.67K | +48% |
| David M. Urso Former President and Chief Executive Officer | $53.53K | – | $880.52K | $934.05K | +4% |
| Richard G. Ghalie Former Chief Medical Officer | $43.87K | – | $664.27K | $708.13K | -16% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had five employees whom all reside in the United States and were engaged in business development, finance, information systems or administrative support.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?